CS
GRTX

Credit Suisse’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History

Credit Suisse’s Portfolio GRTX Stock Details GRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-97,946
Closed -$450K – 4458
2021
Q4 		$450K Buy
+97,946
New +$324K ﹤0.01% 3892

Other funds holding GRTX

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Credit Suisse's GRTX Position: Q1 2022 in Review

Credit Suisse sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q1 2022, closing a stake of 97,946 shares — an estimated $450K sold.

Credit Suisse first reported a position in GRTX in Q4 2021 and held it in 1 quarter. The position peaked at $450K in Q4 2021. 47 funds tracked by Wall St. Rank hold GRTX as of Q1 2022.

  • Credit Suisse reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Credit Suisse sold 97,946 Galera Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $450K.
  • Credit Suisse first reported a position in Galera Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Credit Suisse's Galera Therapeutics, Inc. Common Stock position peaked at $450K in Q4 2021.
  • 47 funds tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Credit Suisse's 13F filing for Q1 2022, filed 16 May 2022.